Richard B. Kim, MD, FRCPC, Division Chair
Dr. Kim received his medical degree from University of Saskatchewan, Canada in 1987. After completing an internship and residency training at Royal University hospital in Saskatoon Canada in 1991, he went on to carry out postdoctoral fellowship training in Clinical Pharmacology at Vanderbilt University.
In 1994, upon completion of his fellowship training, he remained at Vanderbilt Clinical Pharmacology as a faculty member until 2006. He is currently Professor and Chair of the Division of Clinical Pharmacology in the Department of Medicine at the University of Western Ontario in London, Canada. His research interest is that of understanding the molecular basis of interindividual differences in drug disposition and the application of such finding to the emerging field of Personalized Medicine.
Research areas under active investigation in his laboratory include that of drug transporters, CYP enzymes, and the pathways involved in the regulated expression of such proteins. He is a member of ASCPT, ISSX, and AAPS. He is an editor for the Medical Letter Handbook of Adverse Drug Interactions, and an associate editor for Molecular Pharmacology. He is a fellow of AAPS, and member of the American Society for Clinical Investigation (ASCI).

Publications
2000  2001  2002  2003  2004
<<<        >>>

Dishy V., Gupta S., Landau R., Xie H.G., Kim R.B., Smiley R.M., Byrne D.W., Wood A.J.J., and Stein C.M.: G-protein beta3 subunit 825 C/T polymorphism is associated with weight gain during pregnancy. Pharmacogenetics, 13:241-242, 2003. [Pubmed]

Dresser G.K., Schwarz U.I., Wilkinson G.R., and Kim R.B.: Coordinate induction of both CYP3A and MDR1 by St. Johnâ??s Wort in healthy subjects. Clin. Pharmacol. Ther., 73:41-50, 2003. [Pubmed]

Floyd M.D., Gervasini G., Masica A.L., Mayo G., George A.E., Bhat K., Kim R.B., and Wilkinson G.R.: Lack of genotype:phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women. Pharmacogenetics, 13:595-606, 2003.  [Pubmed]

Haas D.W., Wu H., Li H., Rosch R., Lederman M.M., Kuritzkes D., Landay A., Connick E., Benson C., Wilkinson G.R., Kessler H., and Kim R.B.: MDR1 gene polymorphisms and phase-1 viral decay during HIV-1 infection- an AACTG study. J. AIDS, 34:295-298, 2003. [Pubmed]

Kim R.B.: Drug Transporters in HIV therapy. Top HIV Med. 11:136-139, 2003 [Pubmed]

Kim R.B.: Organic anion transporting polypeptide transporter family and drug disposition. Eur. J. Clin. Invest., 33(suppl 2):1-5, 2003. [Pubmed]

Lockhart A.C., Tirona R.G., and Kim R.B.: Pharmacogenetics of ABC transporters in cancer chemotherapy. Mol. Cancer Ther., 2:685-698, 2003. [Pubmed]

Pariante C.M., Kim R.B., Makoff A., and Kerwin R.W.: The antidepressant fluoxetine enhances glucocorticoid receptor function in vitro by modulating the membrane steroid transporter. Br. J. Pharmacol., 139:1111-1118, 2003. [Pubmed]

Sofowora G.G., Dishy V.D., Muszkat M., Xie H.G., Kim R.B., Harris P.A., Prasad H., Byrne D., Nair U.B., Wood A.J.J., and Stein C.M.: A common Beta1 adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta blockade. Clin. Pharmacol. Ther., 73:366-371, 2003. [Pubmed]

Takahashi H., Wilkinson G.R., Caraco Y., Muszkat M., Kim R.B., Kashima T., Kimura S., and Echizen H.: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin. Pharmacol. Ther., 73:253-263, 2003. [Pubmed]

Tirona R.G., Leake B.F., Wolkoff A.W., and Kim R.B.: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane x receptor activation. J. Pharmacol. Exp. Ther., 304:223-228, 2003. [Pubmed]

Tirona R.G., Lee W., Leake B.F., Lan L-B., Brimer C., Lamba V., Parviz F., Duncan S.A., Inoue Y., Gonzalez F.J., Schuetz E.G., and Kim R.B.: The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nature Medicine, 9:220-224, 2003. [Pubmed]

Wandel C., Kim R.B., and Stein C.M.: â??Inactiveâ?� excipients such as Cremophor can affect in vivo drug disposition. Clin. Pharmacol. Ther., 73:394-396, 2003. [Pubmed]

Wang P., Kim R.B., Chowdhury J.R., and Wolkoff A.W.: The human organic anion transport protein SLC21A6 (OATP2) is not sufficient for bilirubin transport. J. Biol. Chem., 278:20695-20699, 2003. [Pubmed]

Zheng Y.M., Henne K.R., Charmley P., Kim R.B., McCarver D.G., Cabacungan E.T., Hines R.N., and Rettie A.E.: Genotyping and site-directed mutagenesis of a cytochrome P450 meander Pro-X-Arg motif critical to CYP4B1 catalysis. Toxicol. Appl. Pharmacol., 186:119-126, 2003. [Pubmed]